# US 2023/0141988 A1 · Pharmaceutical composition for use in the treatment of neurological diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0141988 A1
- Document ID: US20230141988A1
- Status: Published application
- Kind: A1
- Application number: 17/633,150
- Filed: 2020-08-07
- Published: 2023-05-11
- Earliest claimed: 2020-08-07
- Assignees: Aclipse One, Inc.
- Applicants: Aclipse One Inc.
- Inventors: Ning Shan
- Web page: https://patentgrep.com/patent/US20230141988A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions for administration to mammals that include (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient that provides pharmacokinetic profiles useful for the treatment of neurodegenerative diseases.

## Claims

### Claim 1

A method of treating a neurodegenerative disease, the method comprising:
administering a pharmaceutical composition comprising (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and at least one pharmaceutically acceptable excipient,
wherein the composition provides a pharmacokinetic profile comprising a t1/2 at about 0.25 to about 4 hours after oral administration to a mammal.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

A method of treating a neurodegenerative disease, the method comprising:
administering a pharmaceutical composition comprising (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and at least one pharmaceutically acceptable excipient,
wherein the composition provides a pharmacokinetic profile comprising a t1/2 at about 0.5 to about 7 hours after intramuscular, subcutaneous, sublingual, buccal, or intranasal administration.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

A method of treating a neurodegenerative disease, the method comprising:
administering a pharmaceutical composition comprising (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and at least one pharmaceutically acceptable excipient,
wherein the composition provides a t1/2 at about 0.05 to about 5 hours after intravenous administration.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition provides a pharmacokinetic profile comprising a Tmax at about 0.25 to about 10 hours after oral administration.

### Claim 11 (depends on 4)

The method of claim 4, wherein the composition provides a pharmacokinetic profile comprising a Tmax at about 0.05 to about 10 hours after intramuscular, subcutaneous, sublingual, buccal, or intranasal administration.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 4)

The method of claim 4, wherein the composition provides a pharmacokinetic profile comprising a Cmax at about 1 ng/mL to about 5000 ng/mL after intramuscular, subcutaneous, sublingual, buccal, or intranasal administration.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the composition provides a pharmacokinetic profile comprising a Cmax at about 10 ng/mL to about 2000 ng/mL after oral administration.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the composition provides a brain to plasma ratio in a mammal for (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol of about 0.1 to about 6 following administration.

### Claim 24 (depends on 1)

The method of claim 1, wherein the composition provides a CSF to plasma ratio in a mammal for (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol of about 0.1 to about 6 following administration.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the composition provides an oral bioavailability of about 2% to about 30% relative to intravenous administration.

### Claim 27

(canceled)

### Claim 28 (depends on 4)

The method of claim 4, wherein the composition provides an intramuscular or subcutaneous bioavailability of about 40% to about 99% relative to intravenous administration.

### Claim 29 (depends on 4)

The method of claim 4, wherein the composition provides a sublingual or buccal bioavailability of about 2% to about 80% relative to intravenous administration.

### Claim 30 (depends on 4)

The method of claim 4, wherein the composition provides an intranasal bioavailability of about 20% to about 80% relative to intravenous administration.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the composition provides an oral bioavailability of about 2% to about 30% relative to intramuscular or subcutaneous administration.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 4)

The method of claim 4, wherein the composition provides a provides an AUClast/Cmax ratio from about 0.01 to about 20 hours after intramuscular or subcutaneous administration.

### Claim 41

(canceled)

### Claim 42 (depends on 4)

The method of claim 4, wherein the composition provides an AUClast/Cmax ratio from about 0.01 to about 20 hours after sublingual or buccal administration.

### Claim 43

(canceled)

### Claim 44 (depends on 4)

The method of claim 4, wherein the composition provides an AUClast/Cmax ratio from about 0.01 to about 20 hours after intranasal administration.

### Claim 45

(canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the composition provides an AUClast/Cmax ratio from about 0.01 to about 20 hours after oral administration.

### Claim 47

(canceled)

### Claim 48 (depends on 7)

The method of claim 7, wherein the composition provides an AUClast/C0 ratio from about 0.0001 to about 20 hours after intravenous administration.

### Claim 49

(canceled)
